RxDoctor Payments Data

Maria Picton, MD

Hematology & Oncology · Greenville, NCNPI 1881751097

Payments from drug & device makers

$1,826in general payments, 2019–2025

Across 101 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$183
  • Astellas Pharma US Inc$162
  • Johnson & Johnson$161
  • Genentech USA, Inc.$156
  • Merck$137
  • Lilly USA, LLC$118
  • plus $909 from 26 others

What the payments were for

  • Food & beverage$1,44379%
  • Education$38321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,826 in reported general payments places this provider in the 35th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$4,849,751
Medicare patients
713
Services billed
269,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide136$1,987,728
RevlimidLenalidomide70$1,381,504
PomalystPomalidomide20$467,944
SprycelDasatinib27$427,409
LenvimaLenvatinib Mesylate15$376,796
LumakrasSotorasib12$238,189
CalquenceAcalabrutinib Maleate13$187,798
VenclextaVenetoclax12$183,429
GilotrifAfatinib Dimaleate11$112,926
Abiraterone Acetate20$88,781
SorafenibSorafenib Tosylate17$75,244
Gamunex-CImmune Globul G/Gly/Iga Avg 4627$41,006
EliquisApixaban26$22,904
XareltoRivaroxaban30$19,316
Hydroxyurea69$2,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$17$1,381,50470 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$69$895,35347 claims
Eisai Inc.Lenvima$14$376,79615 claims
AmgenLumakras$33$238,18912 claims
AstraZenecaCalquence$95$187,79813 claims
Boehringer IngelheimGilotrif$17$112,92611 claims
PfizerEliquis$183$22,90426 claims
Johnson & JohnsonXarelto$161$19,31630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →